Kornimate/medical-research-clean huggingface dataset:
the different effectiveness of single acupoint（pc6 or cv12) vs matching acupoints(pc6 and cv12) in chemotherapy-induced nausea and vomiting

Conditions: to Evaluate the Effectiveness of Acupucnture in the Management of Chemotherapy-induced Nausea and Vomiting

Summary: the purpose of this study is to clarify whether the matching acupoints are more effective than a single point by electro-acupuncture in the management of chemotherapy-induced nausea and vomiting .


Eligibility criteria:
inclusion criteria: 1. be diagnosed as cancer and need to accept chemotherapy. 2. the score of karnofsky ≥70 3. patients of either gender and older than 18 years 4. patients receiving chemotherapy both outpatients and inpatients 5. patients receiving chemotherapy either the first or multiple cycle, but the patient will be taken in only one time 6. to receive chemotherapy containing cisplatin(ddp≥75mg/m2) or joint chemotherapy programmes of anthracyclines(adriamycin≥40mg/m2 or epirubicin≥60mg/m2) 7. life expectancy≥ 6 months 8. willing to participate in the study and be randomized into one of the four study groups. exclusion criteria: 1. to receive radiotherapy and chemotherapy 2. gastrointestinal tumors 3. patients with serious liver disease or abnormal hepatorenal function (ast,act, and tbil are 3 times more than normal, bun and cr are 2 times more than normal) 4. presence of cardiac pacemaker 5. active skin infection 6. nausea and/or vomiting resulting from opioids or metabolic imbalance (electrolyte disturbances) 7. patients unable to provide self-care or communication 8. nausea and/or vomiting resulting from mechanical risk factors (i.e., intestinal obstruction) 9. brain metastases 10. women in pregnant and lactating period
strategies to optimize positive end-expiratory pressure (peep) in patients with acute lung injury

Conditions: Acute Lung Injury; Acute Respiratory Distress Syndrome; Respiratory Failure

Summary: the purpose of this study in patients suffering from acute lung injury is to determine whether positive end-expiratory pressure (peep) setting guided by electrical impedance tomography (eit) influences pulmonary gas exchange, lung mechanics, ventilation/perfusion matching and homogeneity of regional ventilation when compared to other peep setting strategies such as the open lung concept or the ardsnet protocol.


Eligibility criteria:
inclusion criteria: * acute lung injury, need for optimization of ventilatory settings exclusion criteria: * preexisting chronical lung disease, pneumothorax, pace maker, hemodynamical instability, increased intracranial pressure

Keywords: electrical impedance tomography positive end-expiratory pressure regional ventilation delay index
hemodynamic differentiation of tachycardia episodes using tissue perfusion

Conditions: Arrhythmias, Cardiac

Summary: this research study is a prospective, single-center, feasibility study designed to assess the possibility to detect hemodynamic changes during tachycardia episodes using tissue perfusion.

this study is being conducted to evaluate the feasibility to detect hemodynamic changes induced by supra-ventricular or ventricular tachycardia (svt or vt) using tissue perfusion. patients with a standard indication for either an electrophysiological study or an implantable cardioverter defibrillators(icd) implant can be included into this study. tissue perfusion and arterial blood pressure will be monitored and recorded throughout the electrophysiological procedure or icd implant testing. the study will be conducted in two consecutive phases. after completion of study phase i the study phase ii will commence. study phase i will be an acute non-invasive study in patients with an indication for an electrophysiological study, in whom tissue perfusion will be measured non-invasively with an epi-cutaneous tissue perfusion sensor. phase ii will be an acute invasive study in patients with an indication for the implantation of an icd, in whom the tissue perfusion sensor will be placed in the surgically prepared device pocket on the muscular pectoralis or between the muscular pectoralis major and muscular pectoralis minor.

Eligibility criteria:
inclusion criteria: * indication for: an electrophysiological study with ventricular stimulation or the implantation of an implantable cardioverter defibrillator (icd) * patient is at least 18 years old. * patient is able and willing to give informed consent.
docosahexaenoic acid supplementation of women with hypertension in pregnancy to improve endothelial health

Conditions: Hypertension in Pregnancy

Summary: the investigator would like to see if taking a dha supplement at a dose recommended for heart health will improve brachial artery dilation (relaxation) and help blood pressure. as a second goal the investigator would like to see if this supplement can delay preterm delivery by improving heart health. in this research study, the investigator is asking pregnant women with chronic high blood pressure to take expecta (dha - martek biosciences, now known as dsm nutritional lipil) during the last half of their pregnancy until six weeks after they deliver their baby.

the investigator will be supplementing pregnant mothers with expecta. this is an over the counter supplement often used by pregnant and nursing mothers and will be given to expectant mothers during the research study. this dha supplement is available to anyone at most any store. the dose often used over the counter is 200mg, we are testing the heart recommended dose of 1000mg. because the investigator is using the heart health recommended dose and because there may be a health claim, the investigator is doing the study using an fda- food and drug administration ind. ind means investigational drug. this dose has recently been used safely and effectively in pregnancy both here in the united states and in australia in hundreds of women. there are no risks to the fetus as the placenta prefers to transfer this important nutrient for fetal eye and brain development. the large studies done in pregnancy have followed their babies into school age and found no adverse effects.

Eligibility criteria:
inclusion criteria: * pregnant women coming for their 19-20 week ultrasound for fetal anatomy and that have been diagnosed with hypertension by their obstetrician will be eligible for inclusion. exclusion criteria: * exclusions to enrollment will include: women \< 18 years old * bleeding disorders * lupus * autoimmune diseases * the presence of infant congenital (trisomy 13,18, 21, urethral, gastrointestinal and cardiac defects)

Keywords: chronic hypertension in pregnancy pre-term delivery preeclampsia endothelial health docosahexaenoic acid (dha)
comparison of cervical traction versus snag to improve pain and quality of life in cervical radiculopathy

Conditions: Quality of Life; Cervical Radiculopathy

Summary: for the wellness by comparing of cervical traction versus snag to reduce pain and improve quality of life in cervical radiculopathy


Eligibility criteria:
inclusion criteria: * males and females were included. age group 20-50 years. patient suffering with neck pain radiating down the arms. patients with positive spurling test, cervical distraction and upper limb tension test. exclusion criteria: * subject suffering with any systemic diseases of msk. patients already suffering with pain in shoulder and upper extremity which is of local origin. patient with cardiovascular or respiratory disease. patients having osteophytes in cervical vertebrae. hypermobility of cervical region.
effects of a therapeutic exercise program for injuries prevention in wheelchair basketball (wb) players

Conditions: Athletic Injuries; Shoulder Pain; Shoulder Injury

Summary: shoulder pain is the most common symptom of physical dysfunction in wheelchair basketball players. about the 85% of this population had shoulder pain in some moment of their life. some studies suggest that exercise is an important tool as an element to treat and prevent shoulder injuries. for that reason, an intervention program would be a useful tool for prevent shoulder injuries in this population. the purpose of this study is determine the effects of therapeutic exercise program wheelchair basketball players, in order to prevent shoulder injuries.

the hypothesis of the study was that the exercise program was effective to prevent shoulder injuries in this population.

Eligibility criteria:
study population 36 wheelchair basketball players belonging to the male and female preselection spanish wheelchair basketball national team were recruiting during a campus. the inclusion and exclusion criteria were chosen to include a specific population. inclusion criteria: * players belonging to the male and female preselection spanish wheelchair basketball national team. * have the federal license at the spanish sport federation for people with physical disabilities available at the time of the study (2015-2016 season). * for players using wheelchair for daily activities, to use the manual wheelchair at least for 3 hours a day and 6 hours of wheelchair basketball training per week. * for players not using wheelchair for daily activities, to use the manual wheelchair at least for 6 hours of wheelchair basketball training per week. * use wheelchair at least one year before the study and at least one year of experience in the sport competition. * acceptance of informed consent. exclusion criteria: * history of acute injuries in the post-surgical process or dislocation along the year before the study. these conditions may affect the effective of the exercise intervention. * differential diagnosis as acute injuries at cervical region and recent traumatic injury in shoulder one year before the study. the exercise program may not be appropriate for these conditions.

Keywords: exercise therapy shoulder pain shoulder injuries shoulder function prevention wheelchair users
intracervical balloon placement with nitrous oxide administration

Conditions: Labor Pain; Induced; Birth

Summary: this randomized controlled trial aims to compare the effectiveness of nitrous oxide versus oxygen in facilitating the successful placement of a foley balloon catheter for cervical ripening and induction of labor.

this is a single center randomized controlled trial aimed to compare the effectiveness of nitrous oxide versus oxygen in facilitating the successful placement of a foley balloon catheter for cervical ripening and induction of labor. pregnant women requiring labor induction will be randomly assigned to receive either nitrous oxide or oxygen during the foley balloon placement. the primary outcome measured will be the success rate of the foley balloon placement, with secondary outcomes including patient comfort, pain levels during the procedure, and any adverse effects. the study seeks to determine if nitrous oxide can improve the success rate of foley balloon placement compared to oxygen and to evaluate the overall patient experience and safety associated with its use in this context.

Eligibility criteria:
inclusion criteria: * patients admitted to labor and delivery for induction of labor (term inductions, medically indicated preterm inductions). * pregnant patients who are eligible for intracervical balloon placement. exclusion criteria: * pregnant patients with contraindications to receiving nitrous oxide. * inability to safely self-administer nitrous oxide * allergy to nitrous oxide * history of malignant hyperthermia, * concomitant administration of magnesium sulfate * less than 35 weeks gestational age * non-reassuring fetal heart tracing * use of intravenous or intramuscular opioid within 4 hours * vitamin b12 deficiency * gas-trapping conditions such as pneumothorax or small bowel obstruction * patients requesting neuraxial anesthesia * non-english speaking patients.

Keywords: pregnancy
rebamipide and sjögren syndrome

Conditions: Improving Symptoms of Dry Mouth in Sjőgren's Syndrome

Summary: xerostomia is a major distressing symptom in sjőgren's syndrome(ss). preclinical and clinical studies have demonstrated an increase in saliva volume following rebamipide administration.we thus hypothesize that rebamipide may be efficacious in the treatment of dry mouth symptoms related to sjőgren's syndrome.we will recruit ss patients in a randomized placebo-controlled trial for 12 weeks. the main outcome measure that will concern us is patient-assessed improvement of dry mouth symptoms and increase in salivary secretion safety and efficacy was assessed at each visit.

xerostomia is a major distressing symptom in sjőgren's syndrome (ss). persistent dryness of the mouth causes oral pain, discomfort and significantly interferes with the quality of life. rebamipide, in addition to its gastro-protective effect has displayed various anti-inflammatory actions including inhibition of neutrophilic leukocyte activation. preclinical and clinical studies have demonstrated an increase in saliva volume following rebamipide administration. the aim of the present study is to assess efficacy of rebamipide in the treatment of dry mouth symptoms related to sjőgren's syndrome. methods: fifty-five patients with american european consensus criteria group (aecg)-based diagnosis of ss will participate in this randomized placebo-controlled trial. inclusion criteria will include ss patients with dry mouth symptoms. patients with dry mouth due to other conditions will be excluded. patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy. outcome measures will include patient-assessed improvement of dry mouth symptoms and increase in salivary secretion (evaluation of unstimulated saliva; questionnaires including the visual analogue scale (vas) for sicca-syndrome vas 0-100mm). subjective and objective findings of dry mouth will be recorded at baseline, two, four, six, eight, ten and twelve weeks. safety and efficacy will be assessed at each visit.

Eligibility criteria:
inclusion criteria: * ss patients with dry mouth symptoms exclusion criteria: * patients with dry mouth due to other conditions

Keywords: xerostomia rebamipide efficacy safety
immune boost in non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: insufficient migration and activation of tumour specific effector t cells seems to be the one important reason for inadequate host anti-tumour immune response. ionizing radiation can induce a variety of immune responses. the goal of this randomized trial is to assess if a preoperative single fraction low dose radiation is able to improve anti-tumour immune response in operable early stage lung cancer.


Eligibility criteria:
inclusion criteria: * histologically proven clinical stage i to iia pulmonary adenocarcinoma * lung tumor is felt to be curatively resectable by the treating physicians * sufficient pulmonary function for lobectomy according to current guidelines * the patient is free of distant metastases as confirmed by contrast-enhanced chest and upper abdomen ct-scan and by contrast-enhanced ct or mri of the brain * age over 50years at the time of consent due to federal radiation protection law * in female patients of childbearing potential there must be a negative pregnancy test * eastern cooperative oncology group performance status of 0,1, 2 or 3 at the time of randomization * patients who the investigator believes can and will comply with the requirements of this protocol * written informed consent according to good clinical practise and national/regional regulations exclusion criteria: * the patient shows clinical signs of pneumonia * the patient receives immunosuppressive drugs (alkylating agents, antimetabolites, methotrexate, azathioprine, mercaptopurine, cytotoxic antibodies, ciclosporin, tacrolimus, sirolimus, interferon, mycophenolate, small biological agents) * the patient has been diagnosed with a potential immune mediated disease * elevated blood leukocyte count or erythrocyte sedimentation rate * pregnancy * the patient has received any cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy or chemotherapy * the patient is diagnosed with a concomitant malignancy and/or has a history of malignancy within the past five years or has had a malignancy that has been in complete remission for less than 5 years * the patient needs chronic long term oxygen therapy * the patient has undergone splenectomy * the patient is known to be hiv positive * the patient has an uncontrolled bleeding disorder
preoperative ultrasound evaluation of gastric contents in voluntary termination of pregnancy during the first trimester

Conditions: Voluntary Termination of Pregnancy

Summary: this is an observational, prospective, monocentric, diagnostic study aiming to evaluate the diagnostic properties of the presence of nausea-vomiting in predicting the existence of gastric contents in preoperative surgical abortion.

most surgical abortions are performed under general anaesthesia. inhalation of gastric contents is one of the main complications of general anesthesia, in terms of frequency and severity. patients in the 1st trimester of pregnancy are frequently subject to nausea and vomiting, even on an empty stomach. the presence of nausea and vomiting prior to surgery means that the anesthetic protocol needs to be modified, as there is a greater risk of complications, particularly allergic ones. preoperative gastric ultrasound is recognized for its ability to predict the risk of gastric inhalation during anesthesia. it is a non-irradiating, non-invasive, painless and rapid examination. there are no data on the association between gestational nausea and vomiting and the risk of inhalation in the context of preoperative fasting. there are no data on the gastric volume of patients in the 1st trimester of pregnancy with or without nausea. does gestational nausea and vomiting represent an anesthetic risk of gastric inhalation?

Eligibility criteria:
inclusion criteria: * adult patients * patients undergoing voluntary termination of pregnancy by dilatation and aspiration before 14 weeks of amenorrhea exclusion criteria: * patient under guardianship or curatorship. * patient with language barrier. * any condition causing the patient to be considered as having a "full stomach" even before the gastric ultrasound: * body mass index (bmi) \> 40 kg/m2 * hiatal hernia. * history of gastric or esophageal surgery or neoplasia. * gastroparesis (diabetic, hepatocellular insufficiency, severe renal insufficiency, etc.). * opposition of the patient to the re-use of her data for the study.

Keywords: voluntary termination of pregnancy preoperative gastric content
is tuberculin skin testing effective in screening for latent tuberculosis (tb) in elderly residents of nursing homes?

Conditions: Tuberculosis

Summary: in face of the increased rates of tuberculosis in residents of long term care facilities, annual screening for latent tuberculosis is recommended. tuberculin skin testing using purified protein derivative (ppd) is used for this purpose. sensitivity of the ppd testing is, however, dependent on a normal t cell function. it is now evident that the immune system undergoes age-associated alteration known as immune senescence. the depressed t-cell responses may clinically manifest as attenuated delayed-type hypersensitivity. this attenuated reaction may affect the sensitivity of the ppd in detection of latent tb in the elderly. this prospective study will examine the utility of interferon-gamma (ifn-γ) based assay, t-spot.tb, for detection of latent tuberculosis in nursing home patients who are 65 years of age or older.


Eligibility criteria:
inclusion criteria: * 65 years of age and older * no ulcerating or blistering skin disorder * no previous history of adverse reaction to ppd testing * no blood transfusion within 6 weeks prior to enrollment * if the participant had a ppd placed and read by a public health department representative within the last 6 months, repeat ppd will not be done, but the person may participate in the study * participant may have been bacille de calmette et guerin (bcg)-vaccinated exclusion criteria: * less than 65 years * not a resident of a long term care facility * diagnosis of tuberculosis * blood transfusion within 6 weeks of enrollment * prior diagnosis of immune deficiency

Keywords: latent tuberculosis in elderly
a study comparing bevacizumab therapy with or without erlotinib for first-line treatment of non-small cell lung cancer (atlas)

Conditions: Non-Small Cell Lung Cancer

Summary: this is a phase iiib, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic nsclc.


Eligibility criteria:
inclusion criteria: * signed informed consent form * histologically or cytologically confirmed nsclc * advanced nsclc or recurrent disease * inr no greater than 1.3 and aptt no greater than upper limits of normal (uln) within 28 days prior to enrollment for subjects not on low molecular weight heparin or fondaparinux. subjects on low molecular weight heparin or fondaparinux are not required to meet inr or aptt limits. chronic full-dose anticoagulation with warfarin is not permitted. * 18 years of age or older * for women of childbearing potential and sexually active men, use of an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to enrollment and for the duration of the study exclusion criteria: * prior systemic chemotherapy in the metastatic setting * treatment with an investigational or marketed agent that acts by either egfr inhibition or anti-angiogenesis mechanisms * pregnancy or lactation * any other medical condition, including mental illness or substance abuse, deemed by the clinician to be likely to interfere with a subject's ability to provide informed consent, cooperate, and participate in the study, or to interfere with the interpretation of the results * active infection or a fever within 3 days of enrollment * active malignancy other than lung cancer * radiation therapy to sites other than whole brain within 14 days prior to enrollment * history of gross hemoptysis within 3 months prior to enrollment * known hypersensitivity to any of the components of cytotoxic chemotherapy combinations, bevacizumab, or tyrosine kinase inhibitors * inadequately controlled hypertension * unstable angina or new york heart association grade ii or greater chf * abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrollment * history of myocardial infarction within 6 months prior to enrollment * history of stroke within 6 months prior to enrollment * symptomatic peripheral vascular disease within 6 months prior to enrollment * evidence of bleeding diathesis or coagulopathy * serious, non-healing wound, ulcer, or bone fracture * major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment; anticipation of need for major surgical procedure during the course of the study * current, recent, or planned participation in an experimental drug study other than this genentech-sponsored bevacizumab/erlotinib study * progressive neurologic symptoms in subjects with a history of brain metastases * history of significant vascular disease (e.g., aortic aneurysm)

Keywords: nsclc lung cancer atlas avastin tarceva